Genmab A/S, trading under the symbol NASDAQ:GMAB, is a biotechnology company known for its innovative antibody therapeutics. Established in 1999 and based in Copenhagen, Denmark, Genmab focuses on developing next-generation antibody technology platforms. The company aims to make a significant impact on the lives of people with cancer and other serious diseases by 2030.
In compliance with Article 19 of Regulation No. 596/2014 on Market Abuse, Genmab has disclosed share transactions by its managerial employees and their closely associated persons. This transparency is crucial for maintaining investor trust and aligns with regulatory requirements. The company has been authorized by these individuals to publish details of their trading activities.
Recently, Genmab’s stock has seen positive analyst attention. On March 10, 2025, William Blair upgraded GMAB from Market Perform to Outperform, with the stock priced at $21.98. The following day, Asthika Goonewardene from Truist Financial set a price target of $45, suggesting a potential increase of approximately 77.89% from the then-current price of $20.26.
Currently, GMAB is trading at $20.52, reflecting a 2.81% increase with a change of $0.56. The stock has fluctuated between $20.52 and $21.07 today. Over the past year, it reached a high of $31.02 and a low of $18.64. Genmab’s market capitalization stands at approximately $13.04 billion, with a trading volume of 652,900 shares on the NASDAQ exchange.
